Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Evolutionary Genomics, Inc. (OTC: FNAM).

Full DD Report for FNAM

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-12N/A0.25N/AN/A0
2018-12-11N/A0.25N/AN/A0
2018-12-10N/A0.25N/AN/A0
2018-12-07N/A0.25N/AN/A0
2018-12-06N/A0.25N/AN/A33

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-11-153,0313,031100.0000Short
2018-07-311010100.0000Short
2018-03-092,5002,500100.0000Short
2018-03-021,0002,00050.0000Short
2017-08-235001,02548.7805Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FNAM.


About Evolutionary Genomics, Inc. (OTC: FNAM)

Logo for Evolutionary Genomics, Inc. (OTC: FNAM)

The company engages in agricultural research.

 

Contact Information

 

 

Current Management

  • Steve Warnecke / CEO, CFO, President
    • Steve Warnecke was appointed CFO, Treasurer, Secretary and member of the board of directors on June , and has served as a member of the board of directors of Evolutionary Genomics since September . He was appointed as CEO in November . Mr. Warnecke has served as Chairman of the Board of Directors and CFO for VetDC, Inc. since November and as President and a member of the Board of Directors of CereScan since October . Previously, he served as Senior VicePresident of Children s Hospital Colorado Foundation from April through October and was a member of the Board of Bone Biologics, Inc. from November to February . Mr. Warnecke served as Lead Independent Director and Audit Committee Chair for Evolving Systems, Inc. NASDAQ: EVOL from to January , as CFO of Targeted Medical Pharma, Inc. from January to May , as CFO and member of the Board of Directors for Bacterin International, Inc. NASDAQ: BONE ,from to , member of the Board of Directors of Emmaus Life Sciences, Inc. in , member of the Board of Directors of Boppy Company from to , Senior VicePresident of Strategic Planning for First Data/Western Union NYSE: FDC from to and CFO for Frontier Airlines former NASDAQ company acquired by Republic Airways from to .
  • Walter Messier / Secretary, Treasurer
    • Walter Messier, Ph.D. was appointed Secretary and Treasurer of the Company on October , . He is a Founder of Evolutionary Genomics and has served as its Chief Technology Officer since and has served as its Secretary since . Dr. Messier has published in such prestigious scientific journals as Nature, Nature Medicine, Current Biology, and Science. Dr. Messier is recognized as an authority on the use and interpretation of Ka/Ks algorithms. Dr. Messier s research on the detection of molecularlevel positive selection in the primates is well known. In addition to the research programs Dr. Messier developed and spearheads at Evolutionary Genomics, he is currently collaborating with colleagues in several areas, including identification and validation of novel targets for breast cancer therapeutics, identification and validation of novel targets for HIV/AIDS therapeutics, the role of molecular Darwinian selection in human speciation, and creation of more powerful algorithms for the detection of molecular Darwinian selection. Dr. Messier received his Masters of Science from the State University of New York at New Paltz, and his Ph.D. from the University of Albany State University of New York .
  • Steve Warnecke / Chairman
    • Steve Warnecke was appointed CFO, Treasurer, Secretary and member of the board of directors on June , and has served as a member of the board of directors of Evolutionary Genomics since September . He was appointed as CEO in November . Mr. Warnecke has served as Chairman of the Board of Directors and CFO for VetDC, Inc. since November and as President and a member of the Board of Directors of CereScan since October . Previously, he served as Senior VicePresident of Children s Hospital Colorado Foundation from April through October and was a member of the Board of Bone Biologics, Inc. from November to February . Mr. Warnecke served as Lead Independent Director and Audit Committee Chair for Evolving Systems, Inc. NASDAQ: EVOL from to January , as CFO of Targeted Medical Pharma, Inc. from January to May , as CFO and member of the Board of Directors for Bacterin International, Inc. NASDAQ: BONE ,from to , member of the Board of Directors of Emmaus Life Sciences, Inc. in , member of the Board of Directors of Boppy Company from to , Senior VicePresident of Strategic Planning for First Data/Western Union NYSE: FDC from to and CFO for Frontier Airlines former NASDAQ company acquired by Republic Airways from to .
  • Mark Boggess / Dr. Mark Boggess has served as a director of Evolutionary Genomics since . He served as a swine and beef cattle extension specialist with the University of Idaho in Twin Falls from to . From to , Dr. Boggess served as President of Salmon Creek Farms, LLC where was responsible for development of the Salmon Creek Farms Natural Pork program and branded product line, at Independent Meat Company in Twin Falls, ID. From to , Dr. Boggess was Director of Animal Science for the National Pork Board. Dr. Boggess also served as the National Pork Board liaison for animal science to producers, academia, media, regulators and the National Pork Producers Council. From to present, Dr. Boggess served as the National Program Leader for Food Animal Production and the National Program Leader for Pasture, Forage and Rangeland Systems for the USDA Agriculture Research Service in Beltsville, Maryland. Currently, Dr. Boggess serves as the Director of the U.S. Dairy Forage Research Center in Madison, WI. In this role Dr. Boggess manages and directs the research programs for scientists and approximately support staff. The USDFRC includes two research farms in rural Wisconsin as well as offices and laboratories on the campus of the University of Wisconsin. Dr. Boggess attended Iowa State University receiving a BS degree in Animal Science in . After receiving an MS degree from Cornell University with a major in Animal Breeding in , Dr. Boggess returned to Iowa State University, receiving his PhD in , also in Animal Breeding.
  • Virginia Orndorff / Virginia Orndorff was appointed as a director of the Company on October , . She has served as a member of the Evolutionary Genomics board of directors since . Ms. Orndorff was appointed Executive Director, Chief Executive Officer and Director of the Colorado Institute for Drug, Device and Diagnostic Development. Since Ms. Orndorff has served as Chief Executive Officer of SixOne Solutions, LLC, an earlystage oncology company. She also currently serves on Colorado s State Board of Pharmacy since . She served as Chief Executive Officer and President of Evolutionary Genomics from to . From to , Ms. Orndorff served as Vice President then President and Chief Executive Officer of GenoPlex, Inc. of Denver and served as Director of Technology/Business Development of NeXstar Pharmaceuticals, Inc. of Boulder, Colorado, from to . From to she served as the Director of Biotechnology Programs for the Colorado Advanced Technology Institute in Denver. Ms. Orndorff was employed by the Georgia Institute of Technology as Manager of a biotechnology startup incubator the Health Science Technology Center from to prior to that for eight years by Genex Corporation of Gaithersburg, Maryland, first as a Laboratory Supervisor then as Manager of Technology Assessment. From to , Ms. Orndorff had served as a Microbiologist at Stanford Research Institute. She received a BA in Biology from the University of California at Santa Cruz, an MA in Microbiology from California State University at San Jose, and an MBA from Loyola College where she graduated second in her class .

Current Share Structure

  • Market Cap: $2,901,698 - 03/13/2018
  • Authorized: 780,000,000 - 03/13/2018
  • Issue and Outstanding: 5,803,396 - 03/13/2018

 


Recent Filings from (OTC: FNAM)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 05 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 13 2017

 

 


Daily Technical Chart for (OTC: FNAM)

Daily Technical Chart for (OTC: FNAM)


Stay tuned for daily updates and more on (OTC: FNAM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: FNAM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FNAM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FNAM and does not buy, sell, or trade any shares of FNAM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/